Back to search
FDAFDA · Food and drugs·Recall number D-0423-2019

Cephalexin for Oral Suspension USP 250mg/5 mL, Rx Only Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited Mandideep 462 046 India --- NDC 68180-441-01

Published February 6, 2019 · Recall initiated: January 9, 2019

Summary

FDA records drug Class II recall D-0423-2019, published February 6, 2019 and initiated January 9, 2019. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 14,400 bottles; Lot: lot F801282, Expiry June 2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; presence of extraneous material in the was observed in area that is between the primary package that is heat sealed and secondary packaging (poly-woven bag) of sucrose (an excipient) used in the finished product.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email if CEPHALEXIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CEPHALEXIN
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Product was distributed to 5 wholesalers, 2 drug chains and 1 supermarket who may have further distributed the product throughout the United States.
Lot
lot F801282, Expiry June 2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cephalexin for Oral Suspension USP 250mg/5 mL, Rx Only Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited Mandideep 462 046 India --- NDC 68180-441-01 recalled?

Yes. FDA published recall D-0423-2019 on February 6, 2019. Reported hazard: CGMP Deviations; presence of extraneous material in the was observed in area that is between the primary package that is heat sealed and secondary packaging (poly-woven bag) of sucrose (an excipient) used in the finished product.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CEPHALEXIN.